The recent surge in funding into niche pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." https://delilahkyzi049916.blogofchange.com/40780362/elite-roller-pharma-the-speculative-bet